Compare ProShares UltraPro QQQ ETF (TQQQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

ProShares UltraPro QQQ ETFTrade

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

ProShares UltraPro QQQ ETF vs State Street SPDR S&P Biotech ETF — how do they compare? ProShares UltraPro QQQ ETF trades at $71.65, while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.

	TQQQ	XBI
Sector	Leveraged / Inverse	Broad Market / Factor
52-Week High	$87.22	$169.55
52-Week Low	$37.89	$93.43

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares UltraPro QQQ ETF

TQQQ, a 3x leveraged ETF tracking the Nasdaq-100, trades at $72.16, down 0.29% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. Recent news highlights its amplified returns during the AI boom but warns of structural costs like volatility decay. The ETF's performance is closely tied to large-cap tech earnings and market sentiment.

The outlook for TQQQ hinges on continued tech sector strength, particularly AI-driven growth, but risks include high volatility and decay from daily rebalancing. Investors face amplified gains or losses, making it suitable only for those comfortable with significant risk. Monitoring underlying index performance and tech earnings is critical for timing entries and exits.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

TQQQ

TQQQ returned 59.18% vs. QQQ's 24.99%, but leverage costs and daily resets reduce its triple return over time.24/7 Wall Street · 13 hours agoNeutral View details →

XBI

Biotech ETF IBB outperformed S&P 500 by 22 points in 3 months amid pharma patent cliff deals.24/7 Wall Street · 2 days agoBullish State Street SPDR S&P Biotech ETF (XBI) rated Buy with 8%-14% returns expected despite prior 76% rallySeeking Alpha · 4 days agoBullish View details →

About ProShares UltraPro QQQ ETF

TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.